Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combination regimens for urothelial carcinoma
ChiCTR2200057408Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of toripalimab in transitional cell carcinoma (TCC), urothelial carcinoma (MIBC) and urothelial carcinoma (UC) (4 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Progression-free survival. Started Mar 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (MIBC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on ChiCTR2200057408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057408.